This summarizes an article about the clinical study ‘VANGUARD’ that was published in The Lancet journal in February 2023. Hereditary angioedema (HAE) is a rare genetic disease that causes swellings throughout the body (called HAE attacks). HAE attacks in the upper airways (including the tongue and vocal cords) can be life threatening by making breathing difficult. HAE attacks may occur frequently and without warning, and people with HAE have a lower quality of life than other peopleThis Plain Language Summary of Publication article from Future Rare Disease summarises the results from a study called VANGUARD. Hereditary angioedema (HAE) is a rare genetic disease that causes swellings throughout the body (called HAE attacks), some of these attacks can be life-threatening. The VANGUARD study tested the safety of a new medicine called garadacimab and assessed whether it could prevent HAE attacks.

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial’ and was published in The Lancet. 

Visit The Lancet using the link to read the article.